“This experimental vaccine is generated from the sequences of many flu viruses and is designed to help protect against many strains over several years,” says Tim Alefantis, Sanofi Pasteur project leader. <--- zika An exclusive license will give Sanofi a monopoly in the research, manufacturing and sale of the technology and will allow Sanofi to exclude competition in the clinical development as well as in the manufacturing and pricing of this technology,” MSF explained in a comment posted Monday, adding that “it is very concerning to see the U.S. government considering locking in a development deal that will limit innovation and will not safeguard affordable access to the resulting vaccine.” - See more at: http://raps.org/Regulatory-Focus/News/2017/01/24/26663/Doctors-Without-Borders-Objects-to-Sanofi-Receiving-an-Exclusive-License-for-a-Zika-Vaccine/#sthash.EAq4TvbB.dpuf